Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06255197

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Adenocarcinoma Adenocarcinoma of Lung Bronchial Neoplasms Carcinoma Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Adenocarcinoma Lung Diseases Lung Neoplasms Lung Squamous Cell Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Non Small Cell Lung Cancer Respiratory Tract Diseases Respiratory Tract Neoplasms Small Cell Lung Carcinoma Small-cell Lung Cancer Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

Location status: Recruiting

Location contact

Fengwei Tan, MD

CONTACT

[email protected]

010-87787790

About this study

Lung cancer is the leading cause of cancer-related deaths in China. The recent decade witnessed rapid evolving of demographics, pathological features and prognoses of patients with surgically resected lung cancers. The introduction of minimally invasive surgery (MIS) concept and techniques, targeted therapy and immunotherapy changed treatment landscape for patients with surgically resected lung cancers. With more early-stage lung cancers discovered due to the application of CT screening, questions focusing on extent of lung resection, lymph node dissection, application of targeted or immune-therapy to early-stage lung cancers are emerging. This study aims to create a cohort of patients with surgically resected lung cancers and an analytic framework to address the aforementioned clinical questions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age above 18.
  • Have received surgical resection for lung malignancies.

Exclusion criteria

  • Participants whose data are of low quality, poor completeness or poor internal linkage.

Treatment and study plan

Primary outcomes

  1. Overall survival

    Time frame: January 2014 to December 2031

    Time from surgery to death from any cause.

Secondary outcomes

  1. Baseline characteristics of included participants

    Time frame: January 2014 to December 2028

    Demographics, symptoms at diagnosis, tobacco exposure, family history, previous medical history, etc.

  2. Treatment patterns of included participants

    Time frame: January 2014 to December 2028

    Extent of lung resection and lymph node dissection, application of certain surgical techniques or not; application of chemotherapy, targeted therapy, immunotherapy and/or radiotherapy before and/or after surgery.

  3. Pathological characteristics of included participants

    Time frame: January 2014 to December 2028

    Location, size, classification, presence or absence of certain pathological features of resected tumor(s); number of metastasized and dissected lymph nodes in each station.

  4. Features associated with overall survival

    Time frame: First analysis is anticipated to be performed from April to August 2024; the final analysis is anticipated in 2032.

    Features within the range of collected baseline characteristics, treatment patterns and pathological characteristics that are associated with overall survival.

Study contacts

Contact information is provided by the study sponsor or research team.

Fengwei Tan, MD-PhD

CONTACT

[email protected]

+8601087787792

Renda Li, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Important dates

Study start
2019
Primary completion
2028
Study completion
2031
First posted
Feb 13, 2024
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.